Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma

Hai-Feng Zhang1,2, Christopher S Hughes1,2, Wei Li3

  • 1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Cancer Discovery
|May 22, 2021
PubMed

Insights

Interleukin-1 receptor accessory protein (IL1RAP) helps Ewing sarcoma cells survive detachment and spread. Targeting IL1RAP may offer a new immunotherapy approach for this childhood cancer.

Area of Science:

  • Oncology
  • Cell Biology
  • Cancer Metastasis

Background:

  • Metastasis requires cancer cells to evade anoikis, or detachment-induced cell death.
  • Oncoproteins can drive metastasis by suppressing anoikis.
  • Ewing sarcoma is a highly metastatic childhood cancer.

Purpose of the Study:

  • Identify mechanisms by which Ewing sarcoma cells overcome anoikis.
  • Determine the role of IL1RAP in Ewing sarcoma metastasis.
  • Evaluate IL1RAP as a potential therapeutic target.

Main Methods:

  • Proteomic screening to identify anoikis suppressors.
  • Investigating IL1RAP function in Ewing sarcoma cell lines.
  • Assessing the impact of IL1RAP inactivation on metastasis.
  • Analyzing IL1RAP expression in normal and tumor tissues.
  • Evaluating anti-IL1RAP antibody efficacy in vitro.

Main Results:

  • Distinct oncoproteins upregulate IL1RAP to suppress anoikis.
  • IL1RAP is induced by oncogenic fusions in Ewing sarcoma.
  • IL1RAP inactivation triggers anoikis and impedes metastasis.
  • IL1RAP maintains redox homeostasis by regulating cyst(e)ine and glutathione levels.
  • IL1RAP is minimally expressed in normal tissues.

Conclusions:

  • IL1RAP is a key driver of anoikis resistance and metastasis in Ewing sarcoma.
  • IL1RAP supports cancer cell survival by maintaining redox balance.
  • IL1RAP is a promising cell-surface target for Ewing sarcoma immunotherapy.